Sustained release formulation of olanzapine pamoate suitable for treating psychotic patients

摘要

Described is a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine (2-methyl-4- (4-methyl-l-piperazinyl) -lOH- thieno[2,3-b] [1,5] benzodiazepine) or olanzapine pamoate or solvates thereof. Also described are olanzapine pamoate salts or solvates thereof. Olanzapine has shown great promise in the treatment of psychotic patients and is currently being marketed for that purpose. Such psychotic patients are often non-compliant, making it difficult to assess whether or not a patient has received the proper dosage of medication. It is especially desired to formulate olanzapine in a depot formulation or as a quick intramuscular formulation to assure consistent and proper dosage of the drug substance and to assume compliance.